Published On: Wed, Nov 18th, 2020

COVID-19 vaccine: Pfizer says analysis shows 3.8% of participants experienced fatigue

NEW YORK (Reuters) – Pfizer Inc on Tuesday updated its analysis of the safety profile of its COVID-19 vaccine seen during its large, late-stage trial, saying that 3.8% of participants experienced fatigue after receiving a second dose of the shot.

Pedestrians walk past Pfizer world headquarters in New York on Monday Nov. 9, 2020. Pfizer announced Wednesday, Nov. 18, 2020, more results in its ongoing coronavirus vaccine study that suggest 3.8% of participants experienced fatigue after receiving a second dose of the shot. (AP Photo/Bebeto Matthews)

It said the updated analysis was based on 8,000 trial participants. Pfizer said in a previous analysis that 3.7% of 6,000 volunteers had experienced fatigue.

Pfizer also added that there was a second adverse event with a frequency of at least 2% in the trial. The U.S. drugmaker said 2% of participants experienced headaches after the second shot.


Disclaimer :- This story has not been edited by The Sen Times staff and is auto-generated from news agency feeds. Source: Reuters


About the Author

%d bloggers like this: